A comprehensive view of Pfizer Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Pfizer submits NDA to FDA for approval of oral Paxlovid nirmatrelvir to treat patients at high risk of severe illness from COVID-19; Paxlovid currently has emergency use authorization in US and had Q1 global sales of US$1.5B

Pfizer, BioNTech supplying US government with 105 million doses of COVID-19 vaccinations in 30 µg, 10 µg, 3 µg doses in US$3.2B deal; firms to supply Omicron-adapted vaccine if it receives FDA emergency use authorization

Pfizer, Roivant Sciences announce Priovant Therapeutics JV; Priovant focused on developing autoimmune disease therapies including oral brepocitinib, a potential first-in-class dual inhibitor of TYK2 and JAK1to treat multiple severe autoimmune diseases

Pfizer reports combination COVID-19 booster based on original vaccine with omicron-specific protection and omicron-specific booster vaccine both increase omicron-fighting antibodies in tests; omicron-specific booster had strongest response against omicron

Fitch: Covid-19 vaccine sales saw strong start to 2022, with Pfizer and Moderna posting stronger-than-expected Q1 sales; 2022 sales could be comparable to significant 2021 numbers, but estimates for 2023 should see more pronounced decrease in market size

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count